Who We Are
Welcome to Nanopharm, an Aptar Pharma Company. We are a pioneering pharmaceutical CRO specializing in the development of innovative OINDP (Orally Inhaled and Nasal Drug Products) solutions. With a focus on nasal and inhaled drug delivery systems, we build that niche knowledge to support you and are committed to increasing the number of drugs administered via these routes to maximize efficacy. At Nanopharm, we harness cutting-edge technologies and scientific expertise to design, formulate, test, analyze, simulate, model, and optimize novel therapies that can be conveniently and effectively delivered through the nasal and respiratory routes, and closely work alongside regulatory bodies to revolutionize the pathways to get these drugs to market. Our dedicated team of researchers and engineers work to develop advanced formulations that are optimized to work with a wide range of drug delivery devices and technologies that we can help you to screen and select. With a relentless pursuit of scientific excellence, Nanopharm strives to improve the lives of millions by transforming the landscape of aerosol-based drug delivery.
Nanopharm's Mission
“To utilize our scientific know-how and technologies in de-risking and expediting development of complex OINDPs for both branded and generic drug product markets.”
Our History
2002
Nanopharm founded as a consultancy specialized in pharmaceutical aerosol and inhalation science by Dr Rob Price and Dr Jag Shur.
2003-2018
Expanded into providing specialized analytical and development services capabilities for inhaled and nasal OINDP products.
2019
Aptar Group acquires Nanopharm.
2022
Open new state-of-the-art facility in Wales, UK to increase capacity, add new services and enable development of new technologies.
2023
Expanded analytical capabilities and quality systems to become cGMP compliant and create one center of excellence in Aptar Pharma for OINDP services from R&D through clinical development and onto the market.
Nanopharm founded as a consultancy specialized in pharmaceutical aerosol and inhalation science by Dr Rob Price and Dr Jag Shur.
2002
Nanopharm founded as a consultancy specialized in pharmaceutical aerosol and inhalation science by Dr Rob Price and Dr Jag Shur.
2003-2018
Expanded into providing specialized analytical and development services capabilities for inhaled and nasal OINDP products.
2019
Aptar Group acquires Nanopharm.
2022
Open new state-of-the-art facility in Wales, UK to increase capacity, add new services and enable development of new technologies.
2023
Expanded analytical capabilities and quality systems to become cGMP compliant and create one center of excellence in Aptar Pharma for OINDP services from R&D through clinical development and onto the market.
Nanopharm Building Trust
For more than two decades Nanopharm has earned the trust of its customers through its dedication to scientific advancement in the field of nasal and inhaled drug delivery. We have developed innovative analytical tests, in-vitro, in-silico and computational modeling tools that allow us to support the accelerated advancement of our customer’s OINDPs to market. This dedication to science has led to our customers relying on and trusting our specialized service offering, while appreciating the valuable insights and data they can provide to support their latest drug device combination product. Our position in the OINDP development space has also led to strong relationships with major regulatory bodies, including the direct sponsorship of research by the U.S. FDA. Nanopharm applies its trusted nasal and inhaled drug product development capabilities to every customer project.
Leadership Team
Nanopharm is led by experienced experts dedicated to the field of OINDP science. Our leadership team has the full backing of our parent organization, Aptar, providing a stable foundation on which our company is built.
Our Scientists
Nanopharm was built to advance nasal and inhaled drug delivery sciences. We built the company with the knowledge and dedication of leading scientific experts in the field. They apply their specialized expertise to every OINDP customer project.
Contact Nanopharm
Contact Nanopharm today to accelerate development of your nasal or inhalation product with our specialized technical knowledge, regulatory support, and unique development capabilities.
